ITGAE and neoplasm: The aim of this study is to clarify the prognostic role of CD103 expression in immune cell as a biomarker across multiple tumors and to verify which region within tumor (epithelial, stromal, or both) and material (TMA or whole section) should be used in the assessment of the marker.